Developing of Target Product Profiles (TPP) to inform product developers, regulatory agencies, procurement agencies and funders on R&D and public health priorities. TPPs are intended to facilitate the most expeditious development of products addressing the greatest and most urgent public health need.
Analysis of the global preclinical antibacterial pipeline.
Analysis of the global clinical antibacterial and antituberculosis pipeline.
Update 2018 published in Lancet Infectious Diseases
Contributing to GARDPs (Global Antibiotic Research and Development Partnership) educational programme REVIVE
Member of the independent Scientific Selection Board of the REPAIR Impact Fund to support ambitious programmes addressing antibiotic resistance.
Member of the Advisory Board of CARB-X, a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Government funded projects to address the problem of bacterial resistance.
Work package leader in the EU funded FP7-HEALTH multinational project AIDA (Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics). AIDA is a 5.5 year project (12/2011 – 5/2017) with 6 Million € funding . Three randomized clinical trials supported by an extensive pharmacokinetic, PK/PD, and bacteriological package will fill the gaps in our knowledge and provide the basis for a more effective and safe treatment with the studied old antibiotics colistin, nitrofurantoin, fosfomycin trometamol, rifampicin, oral minocycline. AIDA is the first academic, structured, co-ordinated and collaborative project to “re-develop” old antibiotics. Its impact includes revised dosing regimens, regulatory changes, and updated knowledge of 50-70 year old drugs that are increasingly used.
Work package leader in the European IMI (Innovative Medicines Initiative) project DRIVE-AB which is a collaborative, multinational, public-private consortium with in-kind support from EFPIA partners (European Federation of Pharmaceutical Industries and Associations). DRIVE-AB is a 3 year project (10/2014-12/2017) with 6.3 millin € funding plus in kind contributions from EFPIA.
Partner in the IMI project COMBACTE-MAGNET (part of the IMI program Combating Antibiotic Resistance: New Drugs for Bad Bugs, ND4BB): Combatting Bacterial Resistance in Europe – Molecules against Gram-Negative Infections. COMBACTE-MAGNET is a 7 year project (1/2015-12/2021) with with 75 million € funding plus in kind contributions from EFPIA.
